<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04870346</url>
  </required_header>
  <id_info>
    <org_study_id>531-005</org_study_id>
    <nct_id>NCT04870346</nct_id>
  </id_info>
  <brief_title>Long Term Follow-up Observational Study After Clinical Trials of AMG531 (Romiplostim) in Patients With Untreated Aplastic Anemia</brief_title>
  <official_title>Long Term Follow-up Observational Study After Clinical Trials of AMG531 (Romiplostim) in Patients With Untreated Aplastic Anemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kyowa Kirin Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kyowa Kirin Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the long-term efficacy and safety after the end of romiplostim treatment by&#xD;
      observation [up to 5 years] of patients who were registered for Study 531-003/531-004 in&#xD;
      immunosuppressive therapy-naïve patients with aplastic anemia.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">May 10, 2021</start_date>
  <completion_date type="Anticipated">June 30, 2024</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2024</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Hematological response at 2 years after the start of romiplostim treatment in Study 531-003/531-004</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Hematological response at up to 5 years after the start of romiplostim treatment in Study 531-003/531-004</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The duration of hematological response, and the presence or absence of occurrence of new chromosomal abnormality or transformation to AML/MDS.</measure>
    <time_frame>52, 78, 104, 130, 156, 182, 208, 234, 260 weeks</time_frame>
    <description>Duration of hematological response in patients who achieved hematologic response at the completion of Study 531-003/531-004&#xD;
Time courses of Hb level (g/dL)&#xD;
Time courses of platelet count (/μL)&#xD;
Time courses of neutrophil count (/μL)&#xD;
Presence or absence of platelet blood cell transfusion&#xD;
Presence or absence of red blood cell transfusion&#xD;
Presence or absence of G-CSF product administration&#xD;
Dose level and administration period of cyclosporine A&#xD;
Presence or absence of transformation to MDS/AML&#xD;
Presence or absence of occurrence of new chromosome abnormality&#xD;
Time to the start of subsequent treatment or to death&#xD;
Overall survival</description>
  </secondary_outcome>
  <enrollment type="Anticipated">45</enrollment>
  <condition>Aplastic Anemia</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients enrolled in Study 531-003/531-004&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients whose written consent to participate in this research was obtained among&#xD;
             patients registered for Study 531-003/531-004&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who are judged by the investigator or sub-investigator to be unfavorable for&#xD;
             participation in this research&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Hirohito Yamazaki</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kanazawa University Hospital, Blood Transfusion Department</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kanazawa University, College of Medical Pharmaceutical and Health Sciences, School of Medicine, Department of Hematology</name>
      <address>
        <city>Kanazawa</city>
        <state>Ishikawa Prefecture</state>
        <zip>920-0934</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>April 22, 2021</study_first_submitted>
  <study_first_submitted_qc>April 28, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 3, 2021</study_first_posted>
  <last_update_submitted>May 12, 2021</last_update_submitted>
  <last_update_submitted_qc>May 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>aplastic anemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia</mesh_term>
    <mesh_term>Anemia, Aplastic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

